-
Macron warns urgent to strike EU budget deal before French vote runup
-
Argentine protesters, police clash at demo over university funding
-
Zelensky rallies European allies as Trump ties slump
-
US stocks end higher as AI shares stabilize
-
Guardians edge Rays to seize MLB playoff series lead
-
School roof collapse kills 32 children, teacher in Pakistan
-
Trump scraps plan to livestream execution after fierce backlash
-
Lyon down Palace in Europa League, Sunderland leave it late
-
Martinez apologises for outburst at Man Utd hierarchy
-
UniCredit says receives ECB green light for Commerzbank takeover
-
Houthis launch deadly attack on presidential palace in Yemen's Aden
-
New York City pension fund asks Anthropic to delay IPO
-
Brazil forward Antony says home burgled during Betis match
-
Venezuela's Maduro denies US torture charges as 'false accusations'
-
Ravens face familiar foe in Browns coach Monken
-
Somalia sets May presidential election despite insecurity
-
France, Germany reach deal on future of car industry
-
Chelsea's Caicedo eager to be more of a leader
-
Carney campaigns for Canadian unity before Alberta secession vote
-
Rahm reaches separation deal with LIV in bankruptcy court
-
ATP proposes rankings system changes, extra player bonuses
-
UN chief urges nations to end 'war on nature'
-
Russell Brand was 'monster-like', alleged victim tells UK court
-
Newcastle boss Jaissle says Fernandez-Pardo just needs a goal
-
Crowded Launches Crowded MCP, Bringing Nonprofit Financial Operations Into ChatGPT and Claude
-
Infantino offers apology but 'no answers' at FIFA meeting over World Cup plan
-
Albanian PM condemns 'chaos' as violent unrest spreads
-
Don't exclude Turkey from 'Made in Europe' plan: minister to AFP
-
Italian football suffers new blow with Champions League misery
-
French duo Justice to score 'GTA VI': game maker
-
Trump scraps plan to livestream execution after broad backlash
-
El Nino a 'terrifying' threat to coral reefs: UN biodiversity expert
-
Seven missing off Romania after latest Black Sea drone attacks
-
Barcola must get used to Liverpool highs and lows, says Iraola
-
ARKBRIDGE Outlines Jonathan Morelli’s “Picks and Shovels” AI Infrastructure Investment Strategy
-
Versus Trade Wins Best ECN/STP Broker APAC 2026, Marking Third UF Awards Recognition
-
Tech sell-off rolls on as hot inflation data stokes rate worries
-
Three dead as Istanbul sees heaviest rainfall in 80 years
-
McIlroy makes 'solid' start in rain-hit Delhi as Norgaard leads
-
US producer prices see biggest jump since 2022 in added challenge to Trump
-
Seven missing after fire on vessel in Black Sea off Romania
-
Swiatek avoids seed exodus to breeze into Wuhan last eight
-
'Severe drought' declared in parts of UK
-
PM condemns 'chaos' as violent protests grip Albania
-
IUX Announces New Web Client Portal Built for Enhanced Browser-Based Trading
-
'I couldn't breathe', Russell Brand's alleged rape victim says
-
School roof collapse kills teacher, 32 children in NW Pakistan
-
Pope's cancer operation already reshaping papacy
-
Inter skipper Martinez facing month out with thigh injury
-
Zverev cruises past De Minaur to reach Shanghai semi-finals
Appetite-regulating hormones in focus as first Nobel Prizes fall
Research into hormones that regulate appetite is seen leading the race for the Nobel Prize in Medicine, to be awarded Monday -- the first in this year's Nobel season.
At a time when more than one billion people suffer from obesity, research into the hormone called "glucagon-like peptide 1" (GLP-1) could be given the nod for the Nobel Prize in Physiology or Medicine this year, experts said.
A new generation of drugs using GLP-1 agonists -- including blockbuster brands Ozempic, Wegovy and Mounjaro -- has provided a valuable tool to fight obesity and diabetes globally.
"Many are guessing that it (the Nobel Prize in Medicine) will go to the people behind GLP-1," Lars Brostrom, science editor at public broadcaster Sveriges Radio, told AFP.
That could help researchers from major US institutions once again dominate the Nobel Prizes in sciences, which are to be announced this week in Stockholm.
But, even if that happens, US politics is to cast a shadow over them, given budget cuts to science programmes ordered by President Donald Trump's government.
Since January, the US National Institutes of Health (NIH) has terminated 2,100 research grants totalling around $9.5 billion and $2.6 billion in contracts, according to an independent database called Grant Watch.
Such cuts could fuel debate over the growing risk that the United States could lose its edge in scientific research.
"In the post-war period, the US has taken over Germany's role as the world's leading scientific nation," Hans Ellegren, secretary general of the Royal Swedish Academy of Sciences, which awards Nobel Prizes in physics, chemistry, and economics, told AFP.
"When they now start cutting research funding, it threatens the country's position."
- Many contenders -
When it comes to GLP-1, as with many other discoveries, it can be hard to narrow down who exactly deserves to be honoured when many scientists around the world have made significant contributions.
Brostrom said some names often speculated upon are Danish physician Jens Juul Holst, and Joel Habener, a professor of medicine at Harvard, as well as Canadian endocrinologist Daniel Drucker and Yugoslav-born American chemist Svetlana Mojsov.
Despite treatments such as Ozempic being recently introduced, and the Nobel Assembly at the Karolinska Institute more often honouring discoveries that are decades old, "it could also be perfect timing" for GLP-1 recognition "because the discovery itself was made back in the 80s", Brostrom said.
In the same field, research on ghrelin, a hormone that stimulates appetite, could earn a Nobel Prize for two Japanese researchers, Kenji Kangawa and Masayasu Kojima, according to David Pendlebury, who heads research analysis at the firm Clarivate -- which predicts potential Nobel winners based on the number of citations of their work.
Pendlebury said that would also form "a nice bookend to a 1994 discovery" by geneticist Jeffrey Friedman, who discovered another appetite-regulating hormone, leptin, and who has previously been spotlighted by Clarivate.
"We have a combination of very nice discoveries, a hormone for appetite, a hormone that suppresses appetite, and this may also play into a lot of speculation of a prize for the GLP-1," he told AFP.
Clarivate also said the work of German medical professor Andrea Ablasser, American virologist Glen N. Barber, and Chinese-American biochemist Zhijian "James" Chen could be honoured "for elucidating the cGAS-STING pathway, a fundamental mechanism of innate immunity".
It noted that Canadian biologist John E. Dick could also be a contender "for identifying leukaemia stem cells and establishing their relevance in therapy failure".
- 'Invisibility cloak' -
For the Nobel Prize in Physics on Tuesday, experts at Sweden's public radio cited research into metamaterials, which has been buzzed about for several years.
British physicist John B. Pendry has in particular been frequently mentioned for his "invisibility cloak" -- a theoretical method to redirect electromagnetic fields around an object.
The Nobel season continues Wednesday with the prize for chemistry, followed on Thursday by the closely watched literature prize and on Friday the peace prize, which Donald Trump has argued should go to him.
The economics prize wraps up the Nobel season on October 13.
In addition to each honour, the prize includes a diploma, a gold medal, and a check for 11 million Swedish kronor ($1.2 million).
O.Salim--SF-PST